The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome

Psychiatry Investigation

Volumn 6, Issue 3, 2009, Pages 204-210

  Turan, Tayfun ^a   Izgi, Hasan Basri ^a   Ozsoy, Saliha ^a   Tanriverdi, Fatih ^a   Basturk, Mustafa ^a   Asdemir, Akif ^a   Beşirli, Ash ^a   Esel, Ertugrul ^a   Sofuoglu, Seher ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Chronic fatigue syndrome; Cortisol; Dehydroepiandrosterone sulfate; Galantamine hydrobromide

Indexed keywords

GALANTAMINE; HYDROCORTISONE; STERYL SULFATASE;

ADULT; ARTICLE; CHOLINERGIC ACTIVITY; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MALE;

EID: 70350054440     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2009.6.3.204     Document Type: Article

References (45)

1. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959. (Pubitemid 24370860)
2. Farmer A, Jones I, Hilliery J, Llewelyn M, Barysiewicz L, Smith A. Neurasthenia revisited: ICD-10 and DSM-III-R psychiatric syndromes in chronic fatigue patients and comparison subjects. Br J Psychiatry 1995;167:503-506. (Pubitemid 26194153)
3. Luyten P, Van Houdenhove B, Pae CU, Kempke S, Van Wambeke P. Treatment of chronic fatigue syndrome: findings, principles and strategies. Psychiatry Invest 2008;5:209-212.
4. Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, et al. Hypothalamo-pituitary-adrenal axis function in chronic fatigue syndrome and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001a;86:3545-3554. (Pubitemid 32755942)
5. Parker AJR, Wessely S, Cleare AJ. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001;31:1331-1345. (Pubitemid 33040358)
6. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224-1234. (Pubitemid 121000696)
7. Scott LV, Dinan TG. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 1998;47:49-54. (Pubitemid 28066758)
8. Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry 2001;158:641-643. (Pubitemid 32289831)
9. Hamilos DL, Nutter D, Gershtenson J, Redmond DP, Clementi JD, Schmaling KB, et al. Core body temperature is normal in chronic fatigue syndrome. Biol Psychiatry 1998;43:293-302. (Pubitemid 28085677)
10. Moorkens G, Berwaerts J, Wynants H, Abs R. Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome. Clin Endocrinol 2000;53:99-106. (Pubitemid 30646132)
11. Strickland P, Morriss R, Wearden A, Deakin B. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47:191-194. (Pubitemid 28066775)
12. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-348.
13. Rosenfeld RS, Helmann L, Roffwarg H, Weitzman ED, Fukushima DK, Gallagher TF. Dehydroisoandrosterone is secreted episodically and synchronously with cortisol by man. J Clin Endocrinol Metab 1971;33:87-92.
14. Goodyer IM, Herbert J, Altham P, Pearson J, Secher S, Schiers H. Adrenal secretion during major depression in 10-16 year olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med 1996;26:245-256.
15. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992;75:1002-1004.
16. Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe stress illness. J Clin Endocrinol Metab 1985;60:947-952.
17. Scott LV, Svec F, Dinan T. A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. Psychiatry Res 2000;97:21-28. (Pubitemid 30943090)
18. De Becker P, De Meirleir K, Joos E, Campine I, Van Stenberge E, Smitz J. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm and Metab Res 1999;31:18-21.
19. Roberts E, Bologa L, Flood JF, Smith GE. Effects of dehydroepiandrosterone and its sulfate on brain tissue in culture and on memory in mice. Brain Res 1987;406:357-362. (Pubitemid 17048426)
20. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-318.
21. Magri F, Cravello L, Barili L, Sarra S, Cinchetti W, Salmoiraghi F, et al. Stress and dementia: the role of the hypothalamicpituitary-adrenal axis. Aging Clin Exp Res 2006;18:167-170.
22. Cozanitis DA. Galantamine hydrobromide versus neostigmine. A plasma cortisol study in man. Anaesthesia 1974;29:163-168.
23. Walker SW, Lightly ER, Clyne C, Williams BC, Bird IM. Adrenergic and cholinergic regulation of cortisol secretion from the zona fasciculate/ reticularis of bovine adrenal cortex. Endocr Res 1991;17:237-265.
24. Edwards AV, Jones CT. Adrenal cortical and medullary responses to acetylcholine and vasoactive intestinal peptide in conscious calves. J Physiol 1993;468:515-527.
25. Matta SG, Fu Y, Valentine JD, Sharp BM. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998;23:103-113.
26. Blacker CV, Greenwood DT, Wesnes KA, Wilson R, Woodward C, Howe I, et al. Effect of galantamine hydrobromide in chronic fatigue syndrome. JAMA 2004;292:1195-1204.
27. Snorrason E, Geirsson A, Stefansson K. Trial of a selective acetylcholinesterase inhibitor, galantamine hydrobromide, in the treatment of chronic fatigue syndrome. J Chron Fatigue Syndr 1996;2:35-54. (Pubitemid 26314867)
28. Cozanitis D, Dessypris A, Nuuttila K. The effect of galanthamine hydrobromide on plasma ACTH in patients undergoing anaesthesia and surgery. Acta Anaesthesiol Scand 1980;24:166-168. (Pubitemid 10123901)
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edition, text revision. Washington DC: American Psychiatric Association;2000.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61.
31. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA. The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982;141:518-523.
32. Richardson J. Myalgic encephalomyelitis: guidelines for doctors. Journal of Chronic Fatigue Syndrome 2002;10:65-80.
33. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999;353:455-458. (Pubitemid 29067337)
34. Gaab J, Hüster D, Peisen R, Engert V, Heitz V, Schad T, et al. Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom Med 2002;64:951-962. (Pubitemid 35417138)
35. Davis BM, Brown GM, Miller M, Friesen HG, Kastin AJ, Davis KL. Effects of cholinergic stimulation on pituitary hormone release. Psychoneuroendocrinology 1982;7:347-354. (Pubitemid 13137518)
36. Cleare AJ, O'Keane V, Miell JP. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology 2004;29:724-732. (Pubitemid 38521234)
37. Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affect Disord 1999;54:129-137. (Pubitemid 29287682)
38. st World Cong. On Chronic Fatigue Syndrome and Related Disorders, Brussels;1995.
39. Kuratsune H, Yamaguti K, Sawada M, Kodate S, Machii T, Kanakura Y. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med 1998;1:143-146.
40. van Rensburg SJ, Potocnik FC, Kiss T, Hugo F, van Zijl P, Mansvelt E. Serum concentrations of some metals and steroids in patient with chronic fatigue syndrome with reference to neurological and cognitive abnormalities. Brain Res Bull 2001;55:319-325. (Pubitemid 32722177)
41. Ottenweller JE, Sisto SA, McCarty RC, Natelson BH. Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology 2001;43:34-41. (Pubitemid 32041420)
42. Goldberg M, Lichten J. High androgen levels in chronic fatigue patients. J Clin Endocrinol Metab 1995;80:3390-3391.
43. Goodyer IM, Park RJ, Netherton CM, Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatry 2001;179:243-249. (Pubitemid 32844286)
44. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol- dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry 2002;159:1237-1239. (Pubitemid 34743270)
45. Kartalci Ş, Eşel E, Özsoy S, Kula M, Turan T. Neurosteroids and Cognitive Functions in Depressed Woman. Klinik Psikofarmakoloji Bülteni 2008;18:9-21.